Dalton expands sterile fill/finish capabilities
The Toronto-based pharma services company said investment is part of a US$10m facility and capital expansion
Dalton Pharma Services has announced the addition of an automated sterile liquid filling to its manufacturing capacity. Headquartered in Toronto, Canada, Dalton is a contract research, development and manufacturing organisation (RDMO).
The investment, the company said, is part of a ten-million-dollar facility and capital expansion.
“The flexibility and aseptic assurance that this new fill-line provides will enable Dalton to extend services beyond the current clinical stage and accelerate the development of clients` sterile drug products to reach the market, faster,” said Peter Pekos, Dalton CEO and President.
The new fill line, which is a fully automated sterile liquid filling system, allows larger batch sizes (~40 BPM), a broader range of filling volumes and container closure systems. It also provides nitrogen purging and individual bottle serialisation.
The equipment will become operational in Q1 of 2019.